Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Growth 2025-2031
Description
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size is predicted to grow from US$ 5865 million in 2025 to US$ 9962 million in 2031; it is expected to grow at a CAGR of 9.2% from 2025 to 2031.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment. In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Market Driver: The increasing prevalence of cancer, particularly ovarian, breast, and prostate cancers, is a major driver of the PARP inhibitors market. As targeted therapies become more popular for cancer treatment, PARP inhibitors, which work by blocking the repair of DNA damage in cancer cells, have shown promising results in clinical trials, especially for patients with specific genetic mutations such as BRCA1 and BRCA2. The growing recognition of the effectiveness of PARP inhibitors in both monotherapy and combination treatments is driving demand, as these therapies offer personalized treatment options with fewer side effects compared to traditional chemotherapy. Ongoing research and the expansion of indications for PARP inhibitors in other cancers also contribute to market growth.
Market Challenge: One of the key challenges for the PARP inhibitors market is the high cost of these therapies, which limits patient access and increases the financial burden on healthcare systems. Despite their effectiveness, the prices of PARP inhibitors are often prohibitively expensive, particularly for long-term use. Additionally, not all cancer patients benefit from PARP inhibition, and there is a risk of resistance developing over time, which can reduce the long-term efficacy of the drugs. Regulatory hurdles and the need for further clinical evidence to support broader indications also pose challenges to market expansion. As the market evolves, ensuring access and affordability while continuing to innovate will be critical to overcoming these barriers.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%. North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent. In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
LP Information, Inc. (LPI) ' newest research report, the “PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Forecast” looks at past sales and reviews total world PARP (Poly ADP-Ribose Polymerase) Inhibitor sales in 2024, providing a comprehensive analysis by region and market sector of projected PARP (Poly ADP-Ribose Polymerase) Inhibitor sales for 2025 through 2031. With PARP (Poly ADP-Ribose Polymerase) Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PARP (Poly ADP-Ribose Polymerase) Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PARP (Poly ADP-Ribose Polymerase) Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PARP (Poly ADP-Ribose Polymerase) Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Lynparza
Zejula
Rubraca
Talzenna
Other
Segmentation by Application:
Ovarian Cancer
Breast Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Hengrui Medical
Key Questions Addressed in this Report
What is the 10-year outlook for the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market?
What factors are driving PARP (Poly ADP-Ribose Polymerase) Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PARP (Poly ADP-Ribose Polymerase) Inhibitor market opportunities vary by end market size?
How does PARP (Poly ADP-Ribose Polymerase) Inhibitor break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment. In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Market Driver: The increasing prevalence of cancer, particularly ovarian, breast, and prostate cancers, is a major driver of the PARP inhibitors market. As targeted therapies become more popular for cancer treatment, PARP inhibitors, which work by blocking the repair of DNA damage in cancer cells, have shown promising results in clinical trials, especially for patients with specific genetic mutations such as BRCA1 and BRCA2. The growing recognition of the effectiveness of PARP inhibitors in both monotherapy and combination treatments is driving demand, as these therapies offer personalized treatment options with fewer side effects compared to traditional chemotherapy. Ongoing research and the expansion of indications for PARP inhibitors in other cancers also contribute to market growth.
Market Challenge: One of the key challenges for the PARP inhibitors market is the high cost of these therapies, which limits patient access and increases the financial burden on healthcare systems. Despite their effectiveness, the prices of PARP inhibitors are often prohibitively expensive, particularly for long-term use. Additionally, not all cancer patients benefit from PARP inhibition, and there is a risk of resistance developing over time, which can reduce the long-term efficacy of the drugs. Regulatory hurdles and the need for further clinical evidence to support broader indications also pose challenges to market expansion. As the market evolves, ensuring access and affordability while continuing to innovate will be critical to overcoming these barriers.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%. North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent. In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
LP Information, Inc. (LPI) ' newest research report, the “PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Forecast” looks at past sales and reviews total world PARP (Poly ADP-Ribose Polymerase) Inhibitor sales in 2024, providing a comprehensive analysis by region and market sector of projected PARP (Poly ADP-Ribose Polymerase) Inhibitor sales for 2025 through 2031. With PARP (Poly ADP-Ribose Polymerase) Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PARP (Poly ADP-Ribose Polymerase) Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PARP (Poly ADP-Ribose Polymerase) Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PARP (Poly ADP-Ribose Polymerase) Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Lynparza
Zejula
Rubraca
Talzenna
Other
Segmentation by Application:
Ovarian Cancer
Breast Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Hengrui Medical
Key Questions Addressed in this Report
What is the 10-year outlook for the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market?
What factors are driving PARP (Poly ADP-Ribose Polymerase) Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PARP (Poly ADP-Ribose Polymerase) Inhibitor market opportunities vary by end market size?
How does PARP (Poly ADP-Ribose Polymerase) Inhibitor break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
96 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
